How long do you stay on immunotherapy — and who actually decides when it's time to stop?

No single fixed duration applies to everyone. Some regimens follow a pre-planned course — commonly around two years for many checkpoint inhibitor protocols — while others continue as maintenance for as long as a response holds and side effects stay manageable. The actual number is shaped by your cancer type, your oncologist's specific protocol, and how you are responding on scans.

If you have been told "about two years" and are now wondering why, or wondering whether that number is really fixed for you, the rest of this page answers both questions honestly — including where that figure actually comes from.

Two years became a common reference point mainly because several major checkpoint inhibitor trials were designed around a two-year maximum treatment duration, not because research proved two years is the biologically ideal length to stop. It was a practical trial-design choice — trials need a defined endpoint to compare outcomes — that then carried over into everyday clinical practice as a familiar benchmark.

That is worth saying plainly, carefully: two years is a widely used convention, not an evidence-backed ceiling proven to be the ideal length for every cancer type. Some oncologists follow it closely for regimens where it was studied; others reasonably continue, shorten, or extend it based on how a specific patient's cancer and case are behaving. Knowing this helps you ask a better question of your own oncologist than "is two years up yet?" — namely, "why is my protocol built around this number, and does it fit my case?"

For many families, the honest answer is yes, to a degree — repeated sessions mean repeated cost and repeated time away from work or home, and treatment fatigue after months or years on maintenance is real, not a sign of ingratitude. Both are legitimate things to raise with your oncologist, not side issues you should manage quietly on your own.

Costs vary by regimen, cancer type, and how sessions are billed, so this page does not quote a figure that could mislead your own planning. What matters is that your treating team can discuss your specific protocol's expected schedule, and can also discuss genuine alternatives — spacing sessions further apart, reassessing sooner than a standard length, or stopping earlier — where your case supports it. Cost and fatigue are part of the conversation about duration, not separate from it.

For patients whose team agrees it is appropriate, stopping usually means fewer clinic visits and a real reduction in the cost and fatigue that come with ongoing sessions — while follow-up scans continue on an agreed schedule specifically to catch any change early. Stopping is not the same as being discharged from care; it is a shift from active treatment to monitoring.

Choosing to stop, when your oncologist agrees your case supports it, is a real and respected outcome of this process — not a lesser path than continuing indefinitely, and not something to feel you have to justify. Equally, continuing on maintenance when your team recommends it is not a failure to "move on." There is no fixed figure this page can give you for what happens next in either direction; that conversation belongs with your own treating team, based on your own scans and history.

• Can You Stop Immunotherapy After Two Years? — a closer look at what happens specifically at that commonly used milestone.
• What Happens If You Stop Immunotherapy Early? — if cost, fatigue, or side effects mean the standard length isn't realistic for your family.
• Making the Decision to Stop: A Framework for Families — a fuller framework for the shared conversation this page has introduced.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through long-term treatment and duration decisions.

This page is for general information and does not replace a consultation. Treatment-duration conventions described here are drawn from published trial-design and patient-education guidance and describe general practice, not a prediction or guarantee for any individual patient. Decisions to continue, adjust, or stop immunotherapy are made by your treating oncologist together with you, based on your own case.

Thousands have asked exactly this question

Wanting a straight answer about how long treatment will really last is not impatience — it's how informed patients and families plan ahead. Our team talks through your specific case honestly.